Tavo Biotherapeutics today announced the successful closing of a $17 million Series A financing led by Pureos Bioventures with participation by Polaris Partners and continued support from existing ...
Tavo Biotherapeutics Secures $17M to advance glaucoma and retinal disease therapies through clinical development and growth.
BASEL, Switzerland, June 8, 2020 /PRNewswire/ -- BaseLaunch, the Basel Area-based biotech venture accelerator and incubator, and BB Pureos Bioventures, a newly formed Swiss biotech venture capital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results